Molecular monitoring of chronic myeloid leukemia in chronic phase (cml-cp)

Saba Yari,1,* Mehrdad payandeh,2 Mehrnoush aeinfar ,3 Khirollah yari,4 Masoud sadeghi,5

1. Department of Biology, Faculty of Science, University of Maragheh, Marāgheh, Iran.
2. 1. Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran.
3. 2. PhD in Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
4. 4. Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
5. 2. PhD in Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Abstract

Introduction

Quantification of the bcr-abl transcript is recommended to follow-up cml patients that treated by imatinib mesylate (im) as a tyrosine kinase inhibitor. bcr-abl transcripts have been recognized as a molecular marker for response to therapy in cml patients (pts). monitoring of this marker to be more effective for identifying optimal responses and can helps informing the decision to switch to alternative therapies. quantitative reverse transcriptase pcr (q-pcr) of bcr-abl1 rna is a critical laboratory technique for accurate and sensitive monitoring the efficiency of tyrosine kinase inhibitor therapy. the aim of our study was to analyze the molecular response (mr) in kurdish cml patients who are treated with imatinib.

Methods

We studied 60 blood samples from cml patients in chronic phase (cp), 36 females and 24 males, under im treatment and monitored by q-pcr on 12 months. median duration of cml was 5 years (range: 1-15). median duration of im treatment was 4 years (range: 1-10).

Results

40% (24 pts), 28.33% (17 pts) and 15% (9 pts) and respectively had reached early molecular response (emr) at 1.0-2.0 log, major molecular response (mmr) at 3.0 log and deep molecular response (dmr) at 4.0-5.0 log and also undetectable bcr‑abl1 levels (cmr) were achieved in 16.67% (10 pts) at 12 months.

Conclusion

We highlighted the possibility to use of q-pcr as a warning at diagnosis, and may use to identify patients who could benefit of a more scrupulous follow-up.

Keywords

Chronic myeloid leukemia, q-pcr, molecular response, imatinib mesylate